antiarrhythmic medications - MedHelps antiarrhythmic medications Center for Information, Symptoms, Resources, Treatments and Tools for antiarrhythmic medications. Find antiarrhythmic medications information, treatments for antiarrhythmic medications and antiarrhythmic medications symptoms.
This phase II dose-finding study demonstrated that the upper dose of RSD1235 (2 + 3 mg/kg) rapidly and effectively terminated AF compared with lower dose RSD1235 and placebo. There were no serious adverse events associated with RSD1235. In contrast to other anti-arrhythmic drugs used for conversion of recent onset AF, there were no instances of drug-related pro-arrhythmia. Although these initial findings will require confirmation in larger scale clinical trials, this safety profile, coupled with an efficacious and rapid onset, confirms that RSD1235 is a promising new agent for the medical conversion of recent onset AF.. Cardioversion of AF may be accomplished using electrical or pharmacologic approaches. Electrical cardioversion is effective in rapidly restoring sinus rhythm; however, it requires procedural sedation and a suitable recovery period and/or may cause pain after treatment. Experimental data suggest that AF itself conditions the substrate for maintenance of AF and supports the need ...
Ischemia-Related Subcellular Redistribution of Sodium Channels Enhances the Proarrhythmic Effect of Class I Antiarrhythmic Drugs: A Simulation Study. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Arrhythmias can range from incidental, asymptomatic clinical findings to life-threatening abnormalities. In some human arrhythmias, precise mechanisms are known, and treatment can be targeted specifically against those mechanisms. In other cases, mechanisms can be only inferred, and the choice of drugs is based largely on the results of prior experience. Anti-arrhythmic drug therapy can have 2 goals: termination of an ongoing arrhythmia or prevention of an arrhythmia. Unfortunately, anti-arrhythmic drugs not only help to control arrhythmias but also can cause them, especially during long-term therapy. Thus, prescribing anti-arrhythmic drugs requires that precipitating factors be excluded or minimized, that a precise diagnosis of the type of arrhythmia be made, and that the risks of drug therapy can be minimized. ...
Antiarrhythmic medication - What are the classes of antiarrhythmic medications? I, II, III and IV. Class I is divided into ia, ib, and ic. These are sodium channel blockers. An example from this class would be propafenone. Class ii agents are beta-blockers (like metoprolol). Class iii are potassium channel blockers - for example, amiodarone. Class IV are calcium channel blockers, like diltiazem.
For more than 20 years, the classification of antiarrhythmic drugs proposed by Vaughan Williams [1] has held the field. In essence, it is based on the effects of antiarrhythmic agents on the...
Study Flashcards On Antiarrhythmic Agents the script at Cram.com. Quickly memorize the terms, phrases and much more. Cram.com makes it easy to get the grade you want!
METHODS AND RESULTS Patients with ventricular tachyarrhythmias were randomly assigned to undergo serial testing of up to six antiarrhythmic drugs by either EPS (EPS limb) or HM and exercise testing (HM limb). Efficacy predictions were achieved in 108 of 242 patients in the EPS limb (45%) and in 188 of 244 patients (77%) in the HM limb. Left ventricular ejection fraction (LVEF) , 0.25 and presence of coronary artery disease were negative correlates (p , 0.10) of drug efficacy predictions in the EPS limb. In the HM limb, LVEF was the lone univariate correlate of efficacy, although it was only marginally significant (p = 0.107). A multivariate model selected assessment by HM and higher LVEF as independent predictors (p , 0.05) of drug efficacy. The drug evaluation process required an actuarial median time of 25 days in the EPS limb and 10 days in the HM limb (p , 0.0001). ...
TY - JOUR. T1 - Therapeutic Drug Monitoring of Antiarrhythmic Drugs. T2 - Rationale and Current Status. AU - Latini, Roberto. AU - Maggioni, Aldo P.. AU - Cavalli, Augusto. PY - 1990. Y1 - 1990. UR - http://www.scopus.com/inward/record.url?scp=0025287780&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0025287780&partnerID=8YFLogxK. U2 - 10.2165/00003088-199018020-00001. DO - 10.2165/00003088-199018020-00001. M3 - Article. C2 - 2180615. AN - SCOPUS:0025287780. VL - 18. SP - 91. EP - 103. JO - Clinical Pharmacokinetics. JF - Clinical Pharmacokinetics. SN - 0312-5963. IS - 2. ER - ...
Since most of the toxicity associated with class 1B antiarrhythmic drugs is dose-related, this review examines adverse effects seen in both therapeutic pra
Antiarrhythmics are a type of heart medication that prevent and treat abnormal heartbeats. Learn more about antiarrhythmics from Heart & Stroke.
... s are a group of pharmaceuticals that are used to suppress fast rhythms of the heart (cardiac arrhythmias), such as
The Report Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz
Study Flashcards On Block 3: Antiarrhythmics at Cram.com. Quickly memorize the terms, phrases and much more. Cram.com makes it easy to get the grade you want!
treatment and prevention during and immediately after Myocardial infarction, though this practice is now discouraged given the increased risk of ...
Betapace - Betapace is an antiarrhythmic drug used for treating certain types of irregular heartbeat (ventricular arrhythmias). It may also be used for other conditions as determined by your doctor.
Several medications are used to treat, prevent, or lessen the frequency or severity of abnormal heart rhythms. This group of medications is called antiarrhythmics. 
Prespecified criteria for adequate heart rate (HR) control in AF are outlined in Table 1. Rate control was assessed only if the patient was in AF at the time of evaluation. If a patient in the rate-control arm was in SR at a specified visit, rate control was not assessed and not recorded at that visit. Adequate rate control required the initial resting HR to be ≤80 beats/min. If that goal was achieved, a standard 6-min walk test (35)or 24-h ambulatory electrocardiographic recording (Holter monitor) was required to confirm adequate rate control. The approach used was left to the discretion of the treating physician. If both Holter monitoring and a 6-min walk test were performed, rate-control criteria had to be met for both tests. Overall rate control required evidence for resting and exercise rate control, as defined. Tests were repeated until rate control was achieved or when the patient had a change in status or change in drug dosage. Further drug titration was based on the results of these ...
The data show that there is no survival benefit to the strategy of rhythm control in elderly patients with atrial fibrillation. Indeed there were trends toward higher rates of death and stroke among patients treated with rhythm control. Rate control appears to be an acceptable primary strategy in patients with atrial fibrillation. Long term anticoagulation appears warranted in all patients with risk factors for stroke. Risk factors for ischemic stroke in nonvalvular AF include prior thromboembolism, CHF, HTN, age, DM, female gender, BP greater than 160 mmHg and LV dysfunction. As stated in the ACC/AHA guidelines, maximum protection against ischemic stroke in AF is probably achieved with an international normalized ratio (INR) of 2 to 3, whereas an INR range of 1.6 to 2.5 appears to be associated with incomplete efficacy, estimated at approximately 80% of that achieved with higher intensity anticoagulation. ACC/AHA guidelines recommend that physicians individualize the selection of the ...
Introduction: Class I antiarrhythmic drugs increase duration of the excitable gap (EG) during typical atrial flutter whereas intravenous class III drugs decrease the EG. The effect of chronic oral amiodarone therapy on the EG is unknown. Methods and Results: EG was prospectively determined by introducing a premature stimulus and analyzing the response pattern during typical atrial flutter in 30 patients without antiarrhythmic drugs and in 20 patients under chronic oral amiodarone therapy. EG was calculated by the difference between the longest coupling interval leading to resetting and the effective atrial refractory period (EARP). A fully EG was defined by the portion of EG where the response curve of the return cycles was flat. A partially EG was defined by the portion of EG where the return cycle increases while coupling interval decreases. A resetting response curve was constructed by plotting the duration of the return cycle against the value of the coupling interval. Cycle length (CL; 222 ...
Introduction:. Atrial fibrillation is by far the most common heart arrhythmia and is even increasing in prevalence and incidence. Approximately 10% of all cardiologic hospitalizations are due to atrial fibrillation. Several studies have shown older patients with paroxysmal or persistent atrial fibrillation and with minor symptoms related to the arrhythmia do equally well on a frequency control as compared to a rhythm control strategy. However, some of this lack of difference in outcome may be because the benefits by achieving sinus rhythm are outbalanced by the risk of medication with presently known antiarrhythmic drugs together with the only modest efficacy of these drugs. Non-pharmacological treatment of atrial fibrillation has drawn increasing interest over the last decade, and especially percutaneous catheter based ablation strategies have been in focus with promising results on the symptomatic level in several series of patients. Different technologies have been in use with very few ...
Several anti-arrhythmic agents, which are used in treatment of AF, exist. However, the efficacy of these drugs still can be improved. Furthermore, some of them are associated with a wide range of adverse side effects. Therefore, the mechanisms of action of these agents have to be better understood and still can be optimized.. Dronedarone is an anti-arrhythmic agent used in the treatment of AF by maintaining sinus rhythm. It is a derivative of amiodarone and has been developed to reduce the side effects as e.g. thyroid toxicity of its precursor compound.. The aim of this work is to integrate the effects of dronedarone into a model of atrial electrophysiology. In this way, the mechanism of action, i.e. the anti-arrhythmic effects of this agent should be better understood. In previous work, the effects of amiodarone were already integrated into an atrial cell model. Finally, a comparison of both agents and their impact on healthy and electrically remodeled tissue shall be carried out. ...
INTERIM STUDY REPORT Public Safety Committee Sue Tibbs, Chair Oklahoma House of Representatives Interim Study 11-028, Rep. Sue Tibbs and Rep. Ben Sherrer October 3, 2011 Study of making pseudoephedrine a Class III drug and needing a prescription to obtain Darrell Weaver Oklahoma Bureau of Narcotics and Dangerous Drugs Control Drug enforcement is a different type of law enforcement. It is an in-progress crime. Laws must be able to adapt and change. Meth Labs: 2007= 147 2008= 248 2009= 743 2010= 818 In 2004, meth labs cost $1 billion in collateral damage. In 2006, Oregon made pseudoephedrine products a Schedule III or prescription only drug. After enactment, Oregon saw the largest decrease in crime rate in the nation. Meth related hospitalizations went down 35% and meth arrests were reduced 33%. Mississippi enacted similar legislation last year. Meth related incidents dropped 35%, arrests dropped 62% and there was a 76% reduction in the number of children removed from meth houses. The Bureau of ...
Tedisamil (3,7-dicyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo-3,3,1-nonane) is an experimental class III antiarrhythmic agent currently being investigated for the treatment of atrial fibrillation. Tedisamil blocks multiple types of potassium channels in the heart resulting in slowed heart rate. While the effects of tedisamil have been demonstrated in both atrial and ventricular muscle, repolarization is prolonged more efficiently in the atria. Tedisamil is administered intravenously and has a half-life of approximately 8 -13 hours in circulation. Tedisamil is being developed as an alternative to other antiarrhythmics as incidence of additional arrhythmic events is lower compared to other class III agents. Tedisamil also has significant anti-ischemic properties and was initially investigated as a potential treatment for angina until its antiarrhythmic effects were discovered. Tedisamil is manufactured by Solvay Pharmaceuticals Inc. under the proposed trade name Pulzium and is currently ...
Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has an anticholinergic effect on the heart which accounts for many adverse side effects. Disopyramide is available in both oral and intravenous forms, and has a low degree of toxicity. Disopyramides Class 1a activity is similar to that of quinidine in that it targets sodium channels to inhibit conduction. Disopyramide depresses the increase in sodium permeability of the cardiac myocyte during Phase 0 of the cardiac action potential, in turn decreasing the inward sodium current. This results in an increased threshold for excitation and a decreased upstroke velocity. Disopyramide prolongs the PR interval by lengthening both the QRS and ...
The first five months of the MAVERIC registry have provided an estimate of the likely minimum incidence of life threatening ventricular arrhythmias in a defined population. It also suggests that just over half of these patients would satisfy the AVID criteria. In the AVID study the average age of patients was 65 years. MAVERIC patients fulfilling the AVID criteria had a similar mean age of 65.8 years. The AVID trial was stopped prematurely in April 1997 after recruitment of 1016 patients. One year mortality was reduced by 38% in patients treated with an ICD compared with those who received antiarrhythmic drug treatment. This significantly improved prognosis continued in the second and third years, with a 25% reduction in deaths in each year.. An improvement in survival with ICD treatment has been suggested in other studies. Patients with previous myocardial infarction with non-sustained ventricular tachycardia, impaired left ventricular function, and non-suppressible inducible ventricular ...
Department of Radiology, University of Wisconsin - Madison, 600 Highland Ave,SC E1/372, Madison, WI, 53792, Wisconsin, USA1 and department of Diagnostic Radiology and Medical Physics, University Hospi- Given the history of this patient, which also included the use of amiodarone, drug induced lung toxicity - amiodarone pneumonitis - was suspected. The diagnosis was validated by trans-bronchial biopsy. Amiodarone treatment was stopped and treat-ment with corticosteroid treatment was initiated. Amiodarone is a class III anti-arrhythmic drug used for treatment of refractory cardiac tachyarrhyth- mias. It accumulates in the liver and lung, and may lead to potentially fatal pulmonary toxicity in 5% of Amiodarone pneumonitis was first described in 1980. Its prevalence in patients treated with amiodarone reached up to 15%. With higher age and higher dosage of amiodarone, the risk of amiodarone pneu- monitis increases. Due to its long tissue half life, both onset of lung toxicity and clearing following ...
Purchase Advances in Antiarrhythmic Drug Therapy, An Issue of Cardiac Electrophysiology Clinics, Volume 2-3 - 1st Edition. Print Book. ISBN 9781437724295
The side effect profile ofhas been well established. Anticholinergic symptoms are most common, but cardiac toxicity is of greatest concern. In particular, the negative inotropic activity and proarrhythmic potential of disopyramide limits its use in s
The effects of ranolazine on cardiac ion currents at concentrations within the therapeutic range (ie, 2 to 6 μmol/L) include inhibition of IKr, late INa, and late ICa,L. Inhibition of IKr by ranolazine prolongs APD, and its effect to inhibit late INa and late ICa,L abbreviates APD. The net effect and clinical consequence of inhibition of these ion channel currents is a modest increase in the mean QTc interval over the therapeutic range. The drug differs significantly from other agents that block IKr and induce TdP. Ranolazine-induced prolongation of the APD is rate independent (ie, does not display reverse rate-dependent prolongation of APD) and is not associated with EADs, triggered activity, an increase in spatial dispersion of repolarization, or polymorphic ventricular tachycardia. Indeed, rather than displaying arrhythmogenic activity, ranolazine, via its actions to suppress EADs and reduce TDR, possesses significant antiarrhythmic activity, acting to suppress the arrhythmogenic effects ...
We have investigated the concentration-dependent modulation, by the novel class III antiarrhythmic compound NE-10064, of the delayed potassium channel current Iks in isolated guinea pig sinoatrial nodal (SAN) and ventricular cells. At concentrations greater than 1 micron, the drug potently inhibited Iks in each of the cell types investigated. The concentration-dependent inhibition of Iks (IC50 = 700 nM) was the same in ventricular and SAN cells. At near-threshold drug concentrations, we also observed increases of Iks activity in both SAN and ventricular cells. The NE-10064-induced enhancement of Iks was more pronounced at voltages near the Iks activation threshold (0 mV), than at more positive voltages in both cell types. Furthermore, the agonistic effects of the drug were more prominent before steady-state effects of the compound were attained, which suggests parallel agonistic and antagonistic pathways. Our results demonstrate that Iks channels in cells of the sinoatrial node region of the ...
Get Flecainide Acetate Coupon Card by print, email or text and save up to 52% off Flecainide Acetate at the pharmacy. Coupons, discounts, and promos updated 2017.
Vernakalant was originally developed to target the atrial-specific ultrarapid delayed rectifier K+ current (IKur). However, it is a multichannel blocker inhibiting IKur, the transient outward potassium current (Ito), the peak and late Na currents, the rapidly activating delayed rectifier potassium channels (IKr), and the inward-rectifing potassium channels (IKAch and IKATP). It is now thought that although IKur block may contribute to vernakalants antifibrillatory effect, its most important action is through atrial-selective blockade of the peak sodium current.6 The effective refractory period is made shorter during AF, and lengthening the effective refractory period can lead to AF termination. This can be achieved by prolonging the action potential duration (APD), primarily by inhibiting potassium channels, or by blocking sodium channels, which increases cardiac excitation threshold, slows conduction, and creates a period of refractoriness after the action potential has repolarized without ...
ARCA biopharma Release: GencaroTM Demonstrated 74% Risk Reduction for New Onset Atrial Fibrillation in Heart Failure Patients with Genotype Believed to be Found in Nearly 50% of Population - read this article along with other careers information, tips and advice on BioSpace
10.1055/b-0035-121513 18 Cardiac Arrhythmias 18.1 Antiarrhythmic Drugs 18.1.1 Basics Antiarrhythmic drugs play a central role in the treatment of cardiac arrhythmias in childhood. But their use must be weighed critically. There are numerous studies in adults showing that class I antiarrhythmic drugs do not reduce mortality, but even increase it in patients with ventricular tachycardia…
Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects ...
Amiodarone is a commonly used anti-arrhythmic agent, with well-recognized chronic toxicity. Less well known is amiodarones potential to cause acute lung damage, which can be severe or, occasionally, life-threatening. Lungs that have already been exposed to physical insults, such as the lungs of patients undergoing cardiac surgery, are particularly susceptible to acute pulmonary toxicity (APT). Unfortunately, cardiac surgery is one of the clinical scenarios in which amiodarone is most commonly used. After reviewing the data, and even in the context of difficulties and discrepancies in the existing literature, we contend that there is sufficient evidence of amiodarones potentially serious side-effect profile in surgical ICU patients to advise continued caution in its use with this severely ill patient group. We suggest that amiodarone has a potentially important, though underrecognized, role in inducing an APT/ARDS in some patients, such as those undergoing cardiac surgery. We also provide a hypothesis
The purpose of this study is to evaluate the effect of BMS-919373 on atrial fibrillation (AF) through its effect on AF burden (AFB), or the percent of time in AF, in subjects with paroxysmal AF (pAF) when administered orally at a range of doses (2 mg once daily (QD), 5 mg QD, 12 mg QD following a 1-week period of loading doses of 3 mg QD, 8 mg QD and 20 mg QD, respectively) for a total of 4 weeks. It is hypothesized that treatment with BMS-919373 will reduce AF burden as compared to baseline relative to placebo ...
Patients with persistent atrial fibrillation (AF) who respond to ibutilide infusion usually convert to sinus rhythm within 1 hour. However, little is known about the magnitude and time course of the drugs atrial electrophysiological effects. In the current study, the frequency content of the fibrillatory baseline on the ECG was used to quantify the effects of ibutilide infusion on AF. Nineteen patients (age 56 +/- 16 years) in persistent AF were studied. Nine of these were chronically treated with antiarrhythmic drugs. All subjects received ibutilide (1 mg i.v.) over 10 minutes and a second dose 10 minutes later as needed. An ECG was recorded and digitized throughout each of the 20 sessions (one patient had two separate cardioversions). A signal processing technique was then used to quantify the average rate of the fibrillatory baseline. After attenuating the QRS and T waves, the ECG was subjected to Fourier transformation. The average rate of fibrillatory activity was defined as the frequency
The prevalence of sudden cardiac death (SCD) or hemodynamically unstable ventricular tachyarrhthmias (VTA) in patients with heart failure can be as high as 50%.1,2 The use of ICDs have significantly reduced mortality from SCD in patients at the highest risk. However while ICD discharges save lives, they also have associated physical and psychological morbidity.3 Anti-arrhythmic drugs (classes I, II, and III) commonly used for suppression of VTA, have many side effects and can be pro-arrhythmic. Several classes of medications that are used to treat and prevent coronary heart disease may have favorable anti-arrhythmic effects on VTA, including statins, very long chain omega-3 polyunsaturated fatty acids (omega-3 PUFA), and ranolazine. A meta-analysis of 25 trials of statin versus placebo indicated that there was significant reduction in sudden cardiac death in the statin arm OR 0.90 (95% CI 0.82-0.97).24 In general, the majority of these trials were in patients with ischemic cardiomyopathy. There ...
In experimental studies, mostly done in laboratory animals, researchers have reported that n-3 PUFAs have several potential anti-arrhythmic effects40, 41-most notably a direct effect on cardiac ion channels. Initial data37 from single-cell experiments with isolated cardiomyocytes showed that acute application of purified n-3 PUFAs had a profound inhibitory effect on sodium channels, reducing the peak sodium current by more than 50% and shifting the steady-state inactivation towards negative potentials, thus reducing excitability. This finding was supported by other similar studies,38, 39 leading to the hypothesis that n-3 PUFAs exert their predominant anti-arrhythmic effect by their inhibitory action on sodium channels. However, when cardiac cells with high membrane incorporation of n-3 PUFA, which was obtained from animals fed a diet fortified with fish oil, were studied, this effect was not consistently reported. Further studies in laboratory animals revealed that n-3 PUFAs have a diverse ...
Script error: No such module TemplatePar.Expression error: Unexpected , operator. Landiolol (INN) is a drug which acts as a highly cardioselective, ultra short-acting beta blocker. It is used as an anti-arrhythmic agent. ...
The reverse use-dependence observed with GLG-V-13 and KMC-IV-84 in the present experiments has been previously reported for methanesulfonalide class III drugs such as dofetilide (Gwilt et al., 1991;Jurkiewicz and Sanguinetti, 1993), E-4031 (Wettwer et al., 1991), d,l-sotalol (Strauss et al., 1970; Hafneret al., 1988), MK-499 (Baskin and Lynch, 1994; Krafte and Volberg, 1994) and sematilide (Krafte and Volberg, 1994). The actual mechanism(s) for reverse use-dependence is/are controversial. The earliest mechanism for reverse use-dependence of action potential duration was advanced by Hondeghem and Snyders (1990). Experimental data from their laboratory demonstrated a time- and voltage-dependent modulation of Ik with quinidine. Quinidine primarily reduced time-dependent outward potassium currents at negative membrane potentials, with blockade of outward potassium currents becoming less pronounced with depolarization (Roden et al., 1988). Later data, however, have failed to demonstrate a similar ...
Oral route(Tablet;Tablet, Extended Release). Active antiarrhythmic therapy has resulted in increased mortality; the risk of active therapy is probably greatest in patients with structural heart disease. In a meta-analysis, the mortality associated with the use of quinidine was more than 3 times as great as the mortality associated with the use of placebo. Another meta-analysis showed that in patients with various non-life-threatening ventricular arrhythmias, the mortality associated with the use of quinidine was consistently greater than that associated with the use of alternative antiarrhythmics .. Oral route(Tablet, Extended Release). Many trials of antiarrhythmic therapy for non-life-threatening arrhythmias have resulted in increased mortality; the risk of therapy is probably greatest in patients with structural heart disease. In the case of quinidine used to prevent or defer recurrence of atrial flutter or fibrillation, meta-analysis data have shown that the mortality associated with the use ...
Question - Effect of smoking on atrial fibrillation. Ask a Doctor about uses, dosages and side-effects of Nicotine, Ask an Oncologist
Efficacy of Short-Term Antiarrhythmic Drugs Use after Catheter Ablation of Atrial Fibrillation-A Systematic Review with Meta-Analyses and Trial Sequential Analyses of Randomized Controlled Trials. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance ...
This patient has experienced an inferior wall myocardial infarction (MI) as demonstrated by her EKG showing ST segment elevation in leads II, III, and aVF. The treatment discussed in the vignette was most likely immediate revascularization via endovascular cathaterization and stent placement. In the first 24 hours following an MI, patients are at increased risk for arrhythmias. Historically, class IB antiarrhythmics such as lidocaine have been used as prophylaxis because of preferential binding to (ischemic) tissue that has been damaged in the MI. While prophylaxis with these medications is now less common, there is still a role for treatment of ventricular arrhythmias with class IB antiarrhythmics in specific settings, though they must be carefully dosed and monitored as toxicity include CNS effects. This includes lightheadedness, dizziness, drowsiness and confusion in the mild cases and progresses to seizures and respiratory arrest in severe cases ...
A placebo-controlled study of i.v. amiodarone in patients with supraventricular arrhythmias and 2 to 3-consecutive-beat ventricular arrhythmias, and a pharmacokinetic/pharmacodynamic study evaluating rapid i.v. loading in patients with recurrent, refractory ventricular tachycardia (VT)/ ventricular fibrillation (VF) have shown rapid onset of antiarrhythmic activity well before significant blood levels of desethylamiodarone (DEA) were present; approximately 1500 mg/day of i.v. amiodarone were administered using 2- and 3-stage infusion regimens.
In this interview, Dr. Daniel Singer updates us on the new anticoagulants for atrial fibrillation stroke prevention that he presented about at Boston Atrial Fibrillation Symposium.